An interventional study of Smoking cessation multilevel Intervention in Lung Cancer Screening, Tobacco Use Disorder and Smoking Cessation, sponsored by Louisiana State University Health Sciences Center in New Orleans. Recruiting at 2 sites in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Louisiana State University Health Sciences Center in New Orleans · Not applicable, Interventional, and Prevention
This study aims to reduce disparities and the burden of lung cancer among African American smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation (MILS), followed the NIH DEIA strategies using multilevel interventions that impact determinants of health and address health disparities at appropriate time points across the life course.
African Americans have both the highest incidence and mortality of lung cancer compared to any other racial/ethnic group. A possible explanation for this disparity is that African Americans (AA) may be less likely to utilize preventative screenings such as Low-dose computed tomography (LDCT), which has the potential to encourage smokers to quit smoking successfully. In 2021, the USPSTF expanded their lung cancer screening (LCS) recommendations to include individuals ages 50-80 years with at least a 20 pack-year history, increasing the number of eligible U.S. adults. While the expanded criteria are expected to increase the number of high-risk individuals eligible for screening and reduce lung cancer mortality, the impact on racial and ethnic minorities, including African Americans, has shown mixed findings. This is problematic as previous research has found that African Americans may have different quit behaviors than whites. While use of LCS as a teachable moment for tobacco cessation is important, currently, there is no well- integrated, comprehensive, culturally relevant community-engaged, sustainable program. Still, it is not clear whether the synergy effect of smoking cessation and LDCT LCS intervention was observed in both quitting behaviors and LDCT uptake among African-American smokers. To address this urgent public health concern, this study aims to reduce disparities and the burden of lung cancer among AA smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation(MILS), followed the NIH DEIA strategies using multilevel interventions that impact determinants of health and address health disparities at appropriate time points across the life course. Aim 1) Investigate smokers' and providers' attitudes, knowledge, and experiences with the expanded 2021 USPSTF LCS recommendations. Aim 2) Compare the effectiveness of a MILS vs. usual care on the biochemically-validated 7-day point-prevalence tobacco abstinence rates, LDCT uptake, nicotine dependence and stage of change was assessed. Aim 3) Explore barriers and facilitators that influence primary outcomes at the community, provider, and individual levels for the improvement of a multilevel intervention. To date, no study has evaluated the synergy effect of smoking cessation intervention and LDCT LCS in AA populations with multilevel strategies. We will move the field forward by providing effective, scalable interventions to improve both smoking cessation and LDCT lung cancer screening adherence to reduce health disparities promised by large clinical trials that motivated screening guidelines. The results of the study will directly guide the development of targeted strategies to improve lung cancer screening rates among minorities.
1,027 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
This study's planned enrollment of 250 is above the median of 90 across 892 interventional studies indexed under Tobacco Use Disorder.
Browse Tobacco Use Disorder studies →Louisiana State University Health Sciences Center in New Orleans is the lead sponsor of 72 studies on the registry; 12 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
LDCT lung cancer screening
Behavioral: Smoking cessation multilevel Intervention
The intervention will utilize a multilevel intervention based on the Social Ecological Model's individual, institutional, and community levels.
Stage of Change for Smoking Cessation
Stage of change in smoking cessation behavior
Time frame: Baseline, immediately post-intervention, and 6-month follow-up
7-Day Point Prevalence Abstinence Rate
Proportion of participants reporting no smoking in the past 7 days
Time frame: Baseline, immediately post-intervention, and 6-month follow-up
24-Hour Point Prevalence Abstinence Rate
Proportion of participants reporting no smoking in the past 24 hours
Time frame: Baseline, immediately post-intervention, and 6-month follow-up
Daily Cigarette Consumption
Number of cigarettes smoked per day
Time frame: Baseline, immediately post-intervention, and 6-month follow-up
Nicotine Dependence (Fagerström Test for Nicotine Dependence)
Nicotine dependence measured using the Fagerström Test for Nicotine Dependence (FTND), range 0-10, higher scores indicate greater dependence
Time frame: Baseline, immediately post-intervention, and 6-month follow-up
Lung Cancer Screening (LDCT) Uptake
Completion of low-dose computed tomography (LDCT) lung cancer screening, assessed using a validated questionnaire.
Time frame: Baseline, immediately post-intervention, 6 months
Intent to Undergo Lung Cancer Screening
Participant-reported intention to obtain lung cancer screening, assessed using a previously validated questionnaire.
Time frame: Baseline, immediately post-intervention, 6 months
Plan to share: Yes
Started Apr 2025 (actual). Primary completion is estimated for Jun 2029, 50 months after the start.
Of 255 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 50 months is above that.
Counting every sponsor, half of 265 studies reached it within 32 months; a quarter within 17 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Louisiana State University Health Sciences Center in New Orleans